Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H2 2015

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H2 2015

  • Products Id :- GMDHC7292IDB
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H2 2015


Global Markets Direct's, 'Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Review, H2 2015', provides an overview of the Vaginal Atrophy (Atrophic Vaginitis)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Vaginal Atrophy (Atrophic Vaginitis) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Vaginal Atrophy (Atrophic Vaginitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Vaginal Atrophy (Atrophic Vaginitis) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Vaginal Atrophy (Atrophic Vaginitis) Overview 6

Therapeutics Development 7

Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis)-Overview 7

Vaginal Atrophy (Atrophic Vaginitis)-Therapeutics under Development by Companies 8

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Vaginal Atrophy (Atrophic Vaginitis)-Products under Development by Companies 12

Vaginal Atrophy (Atrophic Vaginitis)-Companies Involved in Therapeutics Development 13

Allergan Plc 13

EndoCeutics, Inc. 14

Foamix Pharmaceuticals Ltd. 15

Ligand Pharmaceuticals, Inc. 16

Pantarhei Bioscience BV 17

Peptonic medical AB 18

RestorGenex Corporation 19

TherapeuticsMD Inc. 20

Vaginal Atrophy (Atrophic Vaginitis)-Therapeutics Assessment 21

Assessment by Monotherapy Products 21

Assessment by Target 22

Assessment by Mechanism of Action 24

Assessment by Route of Administration 26

Assessment by Molecule Type 28

Drug Profiles 30

esterol-Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

estradiol hemihydrate-Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

lasofoxifene tartrate-Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

oxytocin-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

prasterone-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

RES-102-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

TX-004HR-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

WC-3011-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

Vaginal Atrophy (Atrophic Vaginitis)-Recent Pipeline Updates 43

Vaginal Atrophy (Atrophic Vaginitis)-Dormant Projects 47

Vaginal Atrophy (Atrophic Vaginitis)-Dormant Projects 47

Vaginal Atrophy (Atrophic Vaginitis)-Product Development Milestones 48

Featured News & Press Releases 48

Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting 48

Sep 09, 2015: TherapeuticsMD Announces Presentations at The North American Menopause Society 2015 Annual Meeting 49

Aug 05, 2015: TherapeuticsMD Receives Patent Allowance for VVA Candidate TX-004HR 49

Jul 17, 2015: Last subject exits Peptonic Medical's phase 2b VVA study 49

Mar 30, 2015: Vulvovaginal atrophy symptoms improve with prasterone treatment 50

Mar 23, 2015: Peptonic Medical's formulation patent to be approved in the USA 51

Mar 18, 2015: Patient recruitment to Peptonic Medical's phase 2b study soon completed 51

Mar 09, 2015: Physicians Visual Assessments Correlate with Objective Measurements of Postmenopausal VVA Patients Treated with TX-004HR VagiCap 51

Feb 20, 2015: Survey Shows Postmenopausal Women with VVA Reported Improved Satisfaction and Quality of Life with VagiCap Investigational Local Estrogen Treatment 52

Feb 06, 2015: Peptonic Medical and Swetox enter collaboration on oxytocin 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Tables

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2015 7

Number of Products under Development by Companies, H2 2015 8

Comparative Analysis by Late Stage Development, H2 2015 9

Comparative Analysis by Clinical Stage Development, H2 2015 10

Comparative Analysis by Early Stage Development, H2 2015 11

Products under Development by Companies, H2 2015 12

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Allergan Plc, H2 2015 13

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by EndoCeutics, Inc., H2 2015 14

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Foamix Pharmaceuticals Ltd., H2 2015 15

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Ligand Pharmaceuticals, Inc., H2 2015 16

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Pantarhei Bioscience BV, H2 2015 17

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by Peptonic medical AB, H2 2015 18

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by RestorGenex Corporation, H2 2015 19

Vaginal Atrophy (Atrophic Vaginitis)-Pipeline by TherapeuticsMD Inc., H2 2015 20

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Stage and Target, H2 2015 23

Number of Products by Stage and Mechanism of Action, H2 2015 25

Number of Products by Stage and Route of Administration, H2 2015 27

Number of Products by Stage and Molecule Type, H2 2015 29

Vaginal Atrophy (Atrophic Vaginitis) Therapeutics-Recent Pipeline Updates, H2 2015 43

Vaginal Atrophy (Atrophic Vaginitis)-Dormant Projects, H2 2015 47

List of Figures

Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H2 2015 7

Number of Products under Development by Companies, H2 2015 8

Assessment by Monotherapy Products, H2 2015 21

Number of Products by Targets, H2 2015 22

Number of Products by Stage and Targets, H2 2015 22

Number of Products by Mechanism of Actions, H2 2015 24

Number of Products by Stage and Mechanism of Actions, H2 2015 24

Number of Products by Routes of Administration, H2 2015 26

Number of Products by Stage and Routes of Administration, H2 2015 26

Number of Products by Molecule Types, H2 2015 28

Number of Products by Stage and Molecule Types, H2 2015 28

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Allergan Plc

EndoCeutics, Inc.

Foamix Pharmaceuticals Ltd.

Ligand Pharmaceuticals, Inc.

Pantarhei Bioscience BV

Peptonic medical AB

RestorGenex Corporation

TherapeuticsMD Inc.

Vaginal Atrophy (Atrophic Vaginitis) Therapeutic Products under Development, Key Players in Vaginal Atrophy (Atrophic Vaginitis) Therapeutics, Vaginal Atrophy (Atrophic Vaginitis) Pipeline Overview, Vaginal Atrophy (Atrophic Vaginitis) Pipeline, Vaginal Atrophy (Atrophic Vaginitis) Pipeline Assessment

select a license

Single User License
USD 2000 INR 143760
Site License
USD 4000 INR 287520
Corporate User License
USD 6000 INR 431280



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Ken Research, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]